𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

✍ Scribed by W. Deenik; B. van der Holt; G. E. G. Verhoef; A. V. M. B. Schattenberg; L. F. Verdonck; S. M. G. J. Daenen; P. Zachée; P. H. M. Westveer; W. M. Smit; S. Wittebol; H. C. Schouten; B. Löwenberg; G. J. Ossenkoppele; J. J. Cornelissen

Book ID
105988835
Publisher
Springer
Year
2006
Tongue
English
Weight
166 KB
Volume
86
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of imatinib versus in
Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment